{"entity":{"type":"insider","cik":"0001825005","url":"/insider/0001825005","json_url":"/insider/0001825005.json","name":"Combs Andrew","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":6,"n_filings":4,"first":"2020-09-29","last":"2025-03-27","span_basis":"filed_date"},"name_variants":[{"name":"Combs Andrew","source":"filing","n_filings":4,"first_seen":"2020-09-29","last_seen":"2025-03-27"}],"transactions":[{"id":4865721,"accession":"0001562180-25-002779","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-25-002779","line_url":"/filing/0001562180-25-002779#line-1","is_derivative":false,"issuer_cik":"0001678660","issuer_name":"Prelude Therapeutics Inc","issuer_ticker":"PRLD","issuer_name_source":null,"issuer_url":"/issuer/0001678660","owner_cik":"0001825005","owner_name":"Combs Andrew","owner_url":"/insider/0001825005","role":"Officer (Chief Chemistry Officer)","officer_title":"Chief Chemistry Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":100000.0,"shares_display":"100,000","price_per_share":0.6925,"price_display":"0.69","price_state":"stated","total_value":69250.0,"total_display":"69,250.00","shares_owned_after":480123.0,"shares_owned_after_display":"480,123","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-25","filed_date":"2025-03-27","scope":"insider"},{"id":3050998,"accession":"0001562180-24-008565","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-24-008565","line_url":"/filing/0001562180-24-008565#line-2","is_derivative":false,"issuer_cik":"0001678660","issuer_name":"Prelude Therapeutics Inc","issuer_ticker":"PRLD","issuer_name_source":null,"issuer_url":"/issuer/0001678660","owner_cik":"0001825005","owner_name":"Combs Andrew","owner_url":"/insider/0001825005","role":"Officer (Chief Chemistry Officer)","officer_title":"Chief Chemistry Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":60000.0,"shares_display":"60,000","price_per_share":1.3667,"price_display":"1.37","price_state":"stated","total_value":82002.0,"total_display":"82,002.00","shares_owned_after":377623.0,"shares_owned_after_display":"377,623","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-12-23","filed_date":"2024-12-26","scope":"insider"},{"id":3050992,"accession":"0001562180-24-008565","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-24-008565","line_url":"/filing/0001562180-24-008565#line-1","is_derivative":false,"issuer_cik":"0001678660","issuer_name":"Prelude Therapeutics Inc","issuer_ticker":"PRLD","issuer_name_source":null,"issuer_url":"/issuer/0001678660","owner_cik":"0001825005","owner_name":"Combs Andrew","owner_url":"/insider/0001825005","role":"Officer (Chief Chemistry Officer)","officer_title":"Chief Chemistry Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3075.0,"shares_display":"3,075","price_per_share":1.15,"price_display":"1.15","price_state":"stated","total_value":3536.25,"total_display":"3,536.25","shares_owned_after":317623.0,"shares_owned_after_display":"317,623","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-12-20","filed_date":"2024-12-26","scope":"insider"},{"id":4189513,"accession":"0001209191-21-069796","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-069796","line_url":"/filing/0001209191-21-069796#line-2","is_derivative":false,"issuer_cik":"0001678660","issuer_name":"Prelude Therapeutics Inc","issuer_ticker":"PRLD","issuer_name_source":null,"issuer_url":"/issuer/0001678660","owner_cik":"0001825005","owner_name":"Combs Andrew","owner_url":"/insider/0001825005","role":"Officer (EVP, Head of Chemistry)","officer_title":"EVP, Head of Chemistry","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4000.0,"shares_display":"4,000","price_per_share":11.6,"price_display":"11.60","price_state":"stated","total_value":46400.0,"total_display":"46,400.00","shares_owned_after":268380.0,"shares_owned_after_display":"268,380","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-12-14","filed_date":"2021-12-15","scope":"insider"},{"id":4189507,"accession":"0001209191-21-069796","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-069796","line_url":"/filing/0001209191-21-069796#line-1","is_derivative":false,"issuer_cik":"0001678660","issuer_name":"Prelude Therapeutics Inc","issuer_ticker":"PRLD","issuer_name_source":null,"issuer_url":"/issuer/0001678660","owner_cik":"0001825005","owner_name":"Combs Andrew","owner_url":"/insider/0001825005","role":"Officer (EVP, Head of Chemistry)","officer_title":"EVP, Head of Chemistry","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4000.0,"shares_display":"4,000","price_per_share":12.12,"price_display":"12.12","price_state":"stated","total_value":48480.0,"total_display":"48,480.00","shares_owned_after":264380.0,"shares_owned_after_display":"264,380","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-12-13","filed_date":"2021-12-15","scope":"insider"},{"id":2738169,"accession":"0001209191-20-052405","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-052405","line_url":"/filing/0001209191-20-052405#line-1","is_derivative":false,"issuer_cik":"0001678660","issuer_name":"Prelude Therapeutics Inc","issuer_ticker":"PRLD","issuer_name_source":null,"issuer_url":"/issuer/0001678660","owner_cik":"0001825005","owner_name":"Combs Andrew","owner_url":"/insider/0001825005","role":"Officer (EVP, Head of Chemistry)","officer_title":"EVP, Head of Chemistry","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000.0,"shares_display":"1,000","price_per_share":19.0,"price_display":"19.00","price_state":"stated","total_value":19000.0,"total_display":"19,000.00","shares_owned_after":260380.0,"shares_owned_after_display":"260,380","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-09-29","filed_date":"2020-09-29","scope":"insider"}],"next_cursor":null,"ledger_fault":false,"count":{"value":6,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":6,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":6},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001678660","name":"Prelude Therapeutics Inc","url":"/issuer/0001678660","role":"Officer (Chief Chemistry Officer)","n_filings":4,"first_seen":"2020-09-29","last_seen":"2025-03-27"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001825005","retrieved_at":"2026-08-21T09:38:17+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-20","last_ingest":"2026-08-21T05:23:33.898496+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}